-
Mashup Score: 9Home - AACR Annual Meeting News - 2 year(s) ago
ATTENDEE SPOTLIGHT
Source: AACR Annual Meeting NewsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Advances in quantitative sciences driving breakthroughs in cancer research - AACR Annual Meeting News - 2 year(s) ago
During a symposium on Monday, April 17, a panel of scientists discussed how they are leveraging quantitative sciences to advance their cancer research. Symposium chair Nagarajan Vaidehi, PhD, discussed her lab’s work using computational methods to study allostery and disordered proteins.
Source: AACR Annual Meeting NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Researchers are targeting RNA splicing machinery to develop novel cancer treatments - AACR Annual Meeting News - 2 year(s) ago
Three investigators on the cutting-edge of cancer research — including symposium chair Olga A. Anczuków, PhD — described efforts to target RNA splicing in cancer and the immune system during an Annual Meeting session on Sunday, April16.
Source: AACR Annual Meeting NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Therapeutic response and regulation of metastasis differ by organ site - AACR Annual Meeting News - 2 year(s) ago
Experts discussed how the microenvironments of different organ sites regulate metastasis and therapeutic response during an Annual Meeting symposium on Monday, April 17. “There are complex interactions between systemic host responses and the local microenvironments,” said symposium chair Mikala Egeblad, PhD.
Source: AACR Annual Meeting NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Experts discuss insights from latest research into clonal hematopoiesis - AACR Annual Meeting News - 2 year(s) ago
Research into clonal hematopoiesis is revealing insights into the initiation of hematologic malignancies, the biology of clonal selection, and the broad consequences of somatic mutations on the function of terminally differentiated blood cells. It’s a “fast-moving field with major clinical implications,” according to session chair Benjamin L. Ebert, MD, PhD.
Source: AACR Annual Meeting NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Joint session examines clinico-genomic cancer data initiatives in the U.S. and Japan - AACR Annual Meeting News - 2 year(s) ago
The AACR and the Japanese Cancer Association organized a joint session that provided an overview of clinico-genomic cancer data initiatives in the U.S. and Japan and examined some of the challenges that arise when analyzing observational, real-world clinico-genomic data. Kenneth L. Kehl, MD, MPH, and Hiroyuki Mano, MD, PhD, chaired the session.
Source: AACR Annual Meeting NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Researchers discuss myeloid-targeted agents for solid tumors during ASCO joint session - AACR Annual Meeting News - 2 year(s) ago
AACR Past President Lisa M. Coussens, PhD, FAACR, and ASCO President Eric P. Winer, MD, FASCO, co-chaired a special session exploring the role of myeloid cells in cancer development and how basic science discoveries are creating opportunities for new therapeutic targets in solid tumors.
Source: AACR Annual Meeting NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Researchers report first disclosures of 12 novel cancer agents - AACR Annual Meeting News - 2 year(s) ago
The AACR Chemistry in Cancer Research working group organized three special sessions at the Annual Meeting that featured first disclosures on the discovery, structure, and mechanism of action of 12 novel cancer agents that have recently entered into phase I clinical trials or will do so in the next few months.
Source: AACR Annual Meeting NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Researchers report first disclosures of 12 novel cancer agents - AACR Annual Meeting News - 2 year(s) ago
The AACR Chemistry in Cancer Research working group organized three special sessions at the Annual Meeting that featured first disclosures on the discovery, structure, and mechanism of action of 12 novel cancer agents that have recently entered into phase I clinical trials or will do so in the next few months.
Source: AACR Annual Meeting NewsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 10Researchers discuss efforts to speed drug approval process by rethinking phase I trials - AACR Annual Meeting News - 2 year(s) ago
Three experts discussed the evolution of phase I trials during an Annual Meeting symposium on Tuesday, April 18. “We must recognize that forward- and reverse-translation are complementary and phase I is the place to do it. The old linear model of moving forward and failing later is not serving us or our patients,” said Shivaani Kummar, MD.
Source: AACR Annual Meeting NewsCategories: Hem/Oncs, Latest HeadlinesTweet
The AACR Annual Meeting is where the cancer research community gathers to expand the frontiers of discovery science and deliver the next breakthroughs in cancer care. You can learn more about the advances presented at #AACR23 in @AACR Annual Meeting News: https://t.co/cYHcxOwk8u